A detailed history of Stifel Financial Corp transactions in Regenxbio Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 149,280 shares of RGNX stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,280
Previous 131,717 13.33%
Holding current value
$1.16 Million
Previous $1.54 Million 1.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.49 - $14.39 $184,235 - $252,731
17,563 Added 13.33%
149,280 $1.57 Million
Q2 2024

Aug 13, 2024

BUY
$11.51 - $21.53 $473,314 - $885,356
41,122 Added 45.39%
131,717 $1.54 Million
Q1 2024

May 13, 2024

BUY
$12.17 - $24.61 $275,601 - $557,318
22,646 Added 33.33%
90,595 $1.91 Million
Q4 2023

Feb 12, 2024

BUY
$12.89 - $20.82 $27,687 - $44,721
2,148 Added 3.26%
67,949 $1.22 Million
Q3 2023

Nov 13, 2023

BUY
$16.46 - $19.99 $95,863 - $116,421
5,824 Added 9.71%
65,801 $1.08 Million
Q2 2023

Aug 14, 2023

BUY
$17.23 - $21.71 $235,671 - $296,949
13,678 Added 29.54%
59,977 $1.2 Million
Q1 2023

May 12, 2023

BUY
$18.08 - $24.55 $217,032 - $294,698
12,004 Added 35.0%
46,299 $875,000
Q4 2022

Feb 13, 2023

BUY
$20.4 - $24.73 $132,538 - $160,670
6,497 Added 23.37%
34,295 $777,000
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $56,572 - $88,931
2,538 Added 10.05%
27,798 $735,000
Q2 2022

Aug 15, 2022

BUY
$19.35 - $35.04 $91,931 - $166,475
4,751 Added 23.17%
25,260 $624,000
Q1 2022

May 13, 2022

BUY
$24.62 - $34.31 $138,512 - $193,028
5,626 Added 37.8%
20,509 $681,000
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $120,005 - $160,113
3,975 Added 36.44%
14,883 $487,000
Q3 2021

Nov 15, 2021

BUY
$29.09 - $45.68 $135,821 - $213,279
4,669 Added 74.84%
10,908 $457,000
Q2 2021

Aug 13, 2021

BUY
$32.46 - $40.48 $202,517 - $252,554
6,239 New
6,239 $242,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $336M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.